Degron Therapeutics
Lily Zou is the Co-founder and CEO of Degron Therapeutics. She is a seasoned executive with comprehensive scientific knowledge in drug discovery and development and extensive business and commercial expertise. Prior to joining Degron, Dr. Zou served as CEO of Fosun Pharma USA, Vice President of Fosun Pharma Group, Healthcare Partner of Fosun Pharma, and Chairman of the Board or Board member of four companies invested by Fosun Pharma. Dr. Zou built and grew Fosun Pharma’s U.S. business and founded Fosun Pharma’s incubator named Fusion Bioventures based in Boston, which invests and incubates early stage innovative biotech companies. Dr. Zou also built a sales and marketing team in the USA for Fosun Pharma drugs and diagnostics, and launched Fosun Pharma’s first products in 2019. Before Fosun, Dr. Zou worked in top management consulting firm (Bain), large pharmas (Novartis/Sandoz, Wyeth, Millennium), and small biotechs (ArQule, Coley).
Dr. Zou received a BS from Beijing University, a PhD in Microbiology and Immunology from Cornell University, and a MBA from MIT Sloan School of Management.
This person is not in any teams
This person is not in any offices
Degron Therapeutics
Dago Bio aims to become the world's leading research and development company for innovative protein degradation drugs-molecular glue-based small molecule new drugs. The Dago team, composed of world-class managers and scientific leaders with international vision and rich industry experience, will focus on the discovery and verification of new, especially undruggable targets of traditional small molecule inhibitors, and the optimization of new compounds. Provide innovative solutions and paths in preclinical and clinical research. It can be used in all therapeutic areas, with the mission of benefiting human health and addressing unmet clinical medical needs.